Last checked at 25 May 2017 11:20
E-THERAPEUTICS PLC
("e-Therapeutics" or the "Company")
NOTIFICATION BY DIRECTOR
Oxford, UK, 25 May 2017 - e-Therapeutics plc (AIM: ETX), the drug discovery company, announces that it was informed on 25 May 2017 by the Company's Chairman, Mr Iain Ross, that on the afternoon of 24 May 2017, Redx Pharma plc ("Redx"), the drug discovery and development company, announced that it had gone into administration.
Redx's shares were suspended from trading on AIM as at 4.35pm yesterday afternoon. Mr Ross was appointed Chairman of Redx on 1 May 2017.
This announcement is being made pursuant to the requirements of AIM Rule 17 and Schedule 2(g)(v) to the AIM Rules for Companies.
For further information, please contact:
Contacts:
e-Therapeutics plc Ray Barlow, CEO Steve Medlicott, Finance Director
| Tel: +44 (0) 1993 883 125 www.etherapeutics.co.uk
|
Numis Securities Limited Michael Meade / Freddie Barnfield (Corporate Finance) James Black (Corporate Broking)
| Tel: +44 (0) 207 260 1000 www.numis.com
|
Instinctif Partners Melanie Toyne-Sewell / Alex Shaw | Tel: +44 (0) 207 457 2020 Email: e-therapeutics@instinctif.com |
About e-Therapeutics plc
e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform. The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.
The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology. The business model is to partner these preclinical drug candidates.
e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.